Related Experiment Video
Updated: Aug 22, 2025
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
Published on: May 9, 2025
Targeting IDH1/IDH2 mutations in gliomas
1Sylvester Comprehensive Cancer Center and Department of Neurology, University of Miami, Miami, Florida, USA.
Purpose Of Review:
Somatic point mutations in the metabolic enzyme isocitrate dehydrogenase (IDH) are a defining feature of the majority of WHO grade 2-3 diffuse glioma and the most powerful positive prognostic factor for survival in gliomas. The purpose is to review experimental therapeutic approaches targeting IDH mutations in gliomas including small-molecule inhibitors, immunotherapies, and agents targeting mutant IDH-induced epigenetic and metabolic vulnerabilities.
Recent Findings:
Extensive preclinical work supports targeting mutant IDH (mIDH) in glioma. In heavily pretreated patients with mIDH glioma, enzyme inhibitors demonstrated to be well tolerated with preliminary evidence of clinical activity in nonenhancing tumors and enhancing tumors when used as single agents. In patients with newly diagnosed WHO grade 3 or 4 astrocytomas, a phase 1 study of a vaccine-targeting IDH1 R132H showed to be well tolerated and demonstrated immunogenicity with a 3-year progression-free and overall survival rates of 0.63 and 0.84, respectively. A variety of ongoing trials aim to target mIDH, including treatments with single agents or combinatory approaches in the upfront or recurrent setting.
Summary:
mIDH are commonly found in gliomas and play a key role in gliomagenesis. This has led to studies using agents to directly inhibit them, immunotherapies, and epigenetic/metabolic drugs with varying and promising results. Ongoing studies may elucidate the precise role of these therapies and the best timing for treatment within the disease course.
Insights
Targeting isocitrate dehydrogenase (IDH) mutations in gliomas shows promise. Experimental therapies including small-molecule inhibitors and immunotherapies are being investigated for improved patient survival.
Area of Science:
- Oncology
- Neuro-oncology
- Molecular Biology
Background:
- Somatic point mutations in isocitrate dehydrogenase (IDH) are prevalent in WHO grade 2-3 diffuse gliomas.
- Mutant IDH (mIDH) is a significant positive prognostic factor for glioma survival.
- mIDH mutations are crucial in glioma development (gliomagenesis).
Approach:
- Review of experimental therapeutic strategies targeting mIDH in gliomas.
- Investigation of small-molecule inhibitors, immunotherapies, and agents targeting mIDH-induced vulnerabilities.
- Analysis of preclinical data and ongoing clinical trials.
Key Points:
- Enzyme inhibitors targeting mIDH are well-tolerated in pretreated patients with preliminary clinical activity.
- A phase 1 vaccine study for IDH1 R132H mutations showed good tolerance and immunogenicity with high survival rates.
- Ongoing trials explore single-agent and combination therapies for mIDH gliomas in various disease settings.
Conclusions:
- mIDH mutations are key targets for novel glioma therapies.
- Experimental approaches including direct inhibition, immunotherapy, and epigenetic/metabolic drugs show promising results.
- Further research is needed to optimize the timing and use of these therapies in glioma treatment.
